Intense Pulsed-Light Therapy for Proliferative Haemangiomas of Infancy
Table 1
Salient clinical characteristics of the 14 infants.
Patient
Gender
Age (month)
Localisation
Size (cm)
FR
Nb T
I (week)
FU (month)
AE
Cutoff F
Fl
Nb P
Add T
1
F
3.5
Scalp and foot
1.5
N
4
2
10
Cr
550–590
30–51
2–6
N
2
F
3.5
Neck
5
P, Bl
3
2–4
10
N
550
26–30
10–15
Oral CS
3
F
3
Cheek
NS
N
4
2-3
30
N
590
42
3
N
4
F
7.5
Chin
2.5
N
5
4–16
24
N
590
26–42
2–6
N
5
F
7.5
Back
NS
N
4
3-4
66
Bl, Ulc
590
30–51
4–8
N
6
M
1.7
Thigh and forearm
NS
N
3
1-2
2.3
Cr
590
46
10–14
N
7
F
2.8
Forehead
0.8
N
1
3
N
590
45
1
N
8
M
5
Cheek, forearm, back, and scalp
NS
N
3
3
11
N
590
45–48
3–5
N
9
M
2.5
Ear meatus
3.5
N
1
5.6
N
590
44
4
N
10
F
1.4
Scalp
1.5
N
3
2–12
3.5
N
590
45
3
N
11
F
8
Eyebrow
NS
N
4
4–8
16
N
550
26–38
2
N
12
M
5
Nose
NS
Bl
1
5
N
550
28
3
N
13
F
3.5
NS
NS
N
6
4–8
10.5
N
550–590
36–51
1
N
14
M
12
Back and hand
NS
N
2
52
24
N
550
26–32
1–3
N
Age = at first visit; FR = functional repercussion (at the time patient was seen) Nb T, I = number of treatments, interval; FU = followup (= last seen at the age mentioned); AE = adverse events cutoff F, Fl, Nb P = cutoff filters (nm), fluence (J/cm²), number of pulses per treatment; Add T = additional treatment F = female; M = male; N = none; NS = not specified, C = clearance P = pain; Bl = bleeding; Ulc = ulceration; Tel = telangiectasias; Cr = crusts CS = corticosteroids.
